Physician profile
Zayan Kanjo
NPI 1407830441
$1,521.34
in general payments reported to CMS, 2019-2025
22 companies · $54.43 in 2025
The $54.43 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $498 · 2020: $314 · 2021: $266 · 2022: $188 · 2023: $71.06 · 2024: $131 · 2025: $54.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $256.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $210.73 | 2019-2023 | Farxiga |
| Glaxosmithkline, LLC. | $191.37 | 2019-2025 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $168.93 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $139.94 | 2021-2022 | |
| Abbvie INC. | $106.20 | 2021-2023 | |
| Lilly USA, LLC | $80.36 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.46 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.80 | 2019-2024 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $74.47 | 2019-2022 | |
| Novo Nordisk INC | $71.95 | 2020-2025 | Rybelsus, Ozempic |
| Arbor Pharmaceuticals, INC. | $52.10 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.02 | 2024 | |
| Pfizer INC. | $39.55 | 2019 | |
| Novartis Pharmaceuticals Corporation | $31.70 | 2019-2020 | |
| Insulet Corporation | $27.05 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $22.53 | 2020 | |
| Amgen INC. | $22.00 | 2025 | Repatha, Otezla |
| Biohaven Pharmaceuticals, INC. | $20.31 | 2021 | |
| Si-Bone, INC. | $19.51 | 2024 | |
| Phadia US INC. | $17.29 | 2019 | |
| Acorda Therapeutics, INC | $14.06 | 2019 | |
| Nabriva Therapeutics, Plc | $11.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zayan Kanjo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.